Physician profile
Shaena Blevins
NPI 1225214786
$11,064.98
in general payments reported to CMS, 2019-2025
50 companies · $2,609 in 2025
The $2,609 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $221 · 2021: $353 · 2022: $1,617 · 2023: $2,351 · 2024: $3,388 · 2025: $2,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,703 · Education: $623 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,702.99 |
| Education | $623.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,734.93 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Ucb, INC. | $1,033.19 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Alexion Pharmaceuticals, INC. | $922.57 | 2022-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $604.17 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $493.37 | 2022-2025 | Austedo Xr, Austedo Xr |
| Biogen, INC. | $394.55 | 2022-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $382.29 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Pfizer INC. | $342.52 | 2023-2025 | |
| Lundbeck LLC | $338.03 | 2022-2025 | Vyepti, Rexulti |
| Idorsia Pharmaceuticals US INC | $328.77 | 2022-2023 | Quviviq |
| Emd Serono, INC. | $307.14 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $306.07 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $254.09 | 2022-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $241.04 | 2022-2025 | Ingrezza, Ongentys |
| Neurelis, INC. | $234.55 | 2023-2025 | Valtoco |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaena Blevins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.